Bladder cancer trials in China

In China 167 Also abroad 626

167 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Not yet taking people in China
Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer
Where
Wuhan
Age
18 years and over
People
70
Run by
Tongji Hospital
See details and how to joinNCT07865611
Phase 3Taking people
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Nanjing, Nanning, Ningbo, Shanghai, Tianjin, Wuhan
Age
18 years and over
People
450 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218380 · EU 2025-522855-25-00
Phase 2Taking people
Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples
Where
Kunming
Age
18 years to 80 years
People
30
Run by
Yunnan Cancer Hospital
See details and how to joinNCT07848854
Phase 3Taking people
Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma
Where
Beijing
Age
18 years and over
People
192
Run by
Peking University First Hospital
See details and how to joinNCT07498907
Phase 1/2Not yet taking people in China
Trop2-Targeted Near-Infrared Fluorescence Imaging-Guided Precise Resection of Non-Muscle Invasive Bladder Cancer
Where
Kunming
Age
18 years to 80 years
People
30
Run by
Yunnan Cancer Hospital
See details and how to joinNCT07800507
Phase 2Not yet taking people in China
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors
Where
Guangzhou
Age
18 years to 75 years
People
42
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07837622
Phase 1Taking people
Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard Therapy
Where
Beijing
Age
18 years and over
People
12
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07835035
Phase 2Not yet taking people in China
A Study to Evaluate the Efficacy and Safety of RAG-01 as Monotherapy and in Combination With Chemotherapy in Patients With Non-muscle Invasive Bladder Cancer (NMIBC).
Where
Shanghai
Age
18 years and over
People
114
Run by
Ractigen Therapeutics.
See details and how to joinNCT07777848
Phase 2Not yet taking people in China
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
Where
Wenzhou
Age
18 years and over
People
106
Run by
First Affiliated Hospital of Wenzhou Medical University
See details and how to joinNCT07189793
Phase 3Taking people
A Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
Where
Beijing, Guangzhou
Age
18 years and over
People
750
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07726992
Phase 1/2Taking people
A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
Where
Beijing, Nanjing
Age
18 years and over
People
180
Run by
Jiangsu Hansoh Pharmaceutical Co., Ltd.
See details and how to joinNCT07468851
No phaseTaking people
Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer
Where
Kunming
Age
18 years to 80 years
People
40
Run by
Yunnan Cancer Hospital
See details and how to joinNCT06972771
Phase 2Not yet taking people in China
TR115 in ARID1A-Mutated Advanced Solid Tumors
Where
Shanghai
Age
18 years to 70 years
People
50
Run by
Tarapeutics Science Inc.
See details and how to joinNCT07793318
Phase 1Not yet taking people in China
A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure
Where
Changsha
Age
18 years to 75 years
People
20
Run by
Xiangya Hospital of Central South University
See details and how to joinNCT07783815
No phaseNot yet taking people in China
Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion: Construction and Preliminary Application
Where
Nanjing
Age
18 years to 80 years
People
40
Run by
Nanjing First Hospital, Nanjing Medical University
See details and how to joinNCT07781956
Phase 1Taking people
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
Where
Jinan
Age
18 years to 75 years
People
299 worldwide
Run by
Huahui Health
See details and how to joinNCT07623369
Phase 2/3Taking people
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Where
Beijing, Chengdu, Guangzhou
Age
18 years and over
People
630 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07129993
Phase 3Taking people
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Where
Beijing
Age
18 years to 80 years
People
453
Run by
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07393542
Phase 2/3Not yet taking people in China
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
Where
Tianjin
Age
18 years and over
People
114
Run by
Tianjin Medical University Second Hospital
See details and how to joinNCT07756008
Phase 1Taking people
A Phase I/II Study of JL19001 Injection Alone or in Combination With BCG in Subjects With High Risk Non-Muscle Invasive Bladder Cancer.
Where
Chengdu
Age
18 years and over
People
18
Run by
Jecho Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07483970
Phase 2Taking people
Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC
Where
Huanggang, Jingzhou, Shiyan, Wuhan, Xiangyang, Yichang
Age
18 years to 75 years
People
54
Run by
Zhiquan Hu
See details and how to joinNCT07741448
Phase 2/3Taking people
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Where
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Tianjin, Wenzhou, Wuhan, Xiamen, Yantai, Zhengzhou
Age
18 years and over
People
470 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07106762
Phase 1Taking people
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Where
Fuzhou, Hangzhou, Luoyang, Tianjin, Wenzhou, Wuhan, Xi'an
Age
18 years to 70 years
People
174
Run by
Shanghai Henlius Biotech
See details and how to joinNCT07518043
Phase 2Taking people
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Where
Shanghai
Age
18 years to 75 years
People
52
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06405425
No phaseTaking people
Development of an AI-Agent for Urological Disease Diagnosis and Treatment
Where
Ganzhou, Guangzhou, Shantou
People
2,000
Run by
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07721935